| |
Unlock the key to seamless eCOA integration for your next clinical trial with IQVIA’s comprehensive Licensing Guide. From understanding licensing requirements to optimizing integration, our guide is your roadmap to streamlined eCOA implementation. 
|
|
Today’s Big NewsMar 5, 2024 |
| By Max Bayer Biogen's executive vice president and head of corporate development, Adam Keeney, Ph.D., says the company is interested in tacking on additional rare disease drugs at a smaller price than the Reata acquisition. The focus is now on clinical-stage products compared to buying commercial medicines. |
|
|
|
By James Waldron In further proof that Roche’s $310 million metabolic therapy bet will pay off, the Big Pharma’s Alnylam-partnered hypertension drug has notched up another phase 2 win. |
By Gabrielle Masson Venture capital investment in biopharma underwent a significant correction in 2023 from the "explosive growth" during the pandemic, with $29.9 billion spent across 920 transactions compared to $36.7 billion in the previous year, according to a new analysis from PitchBook. |
Sponsored by Wacker Biotech Sitting down with Guido Seidel, Managing Director of Wacker Biotech, we explore some of the key challenges, opportunities and innovations for pharmaceutical companies to consider in mRNA manufacturing. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Secure 50% off Your Fierce TMF Summit Pass | LIMITED Passes Available: Use Promo Code LAST25. Secure your spot Today! +(1)+(1).png)
|
|
By Gabrielle Masson Meissa Vaccines is putting its portfolio on hold and laying off staff due to the current fundraising environment, the company told Fierce Biotech. |
Sponsored by NYCEDC Ready to shape the future of life sciences? Discover how NYC's strategic investments are driving change. |
By Helen Floersh The Department of Health and Human Services’ new biomedical research arm, the Advanced Research Projects Agency for Health, is behind on finalizing a plan to avoid unnecessary research duplication with other government health agencies, despite already awarding funds. |
Sponsored by ICON Biotech ICON Biotech survey shows that although challenges remain, optimism returns to strategically savvy biotech innovators |
By Zoey Becker With the counteroffers, the IRA-mandated negotiations period has begun and will continue through August. |
By Angus Liu Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for. |
By Conor Hale The OsteoCool 2.0 system delivers radiofrequency ablation to treat bone tumors, including cancer metastases as well as benign lesions such as osteoid osteomas. |
By Helen Floersh North Carolina-based Catawba Research has named Syed Faridi as its new vice president of global business development, marking an expansion of the CRO's leadership team. |
By Anastassia Gliadkovskaya Provider groups have come out swinging amid the fallout from the Change Healthcare cyberattack, which happened nearly two weeks ago. From the American Hospital Association to the American Medical Association, groups are pressuring the federal government and UnitedHealth Group to take more action to preserve access to care. |
Fierce podcasts Don’t miss an episode |
| The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This week on "The Top Line," Fierce Pharma’s Angus Liu talks with regulatory experts to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. |
|
|---|
|
|
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
